retatrutide clinical trial phase retatrutide ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide Phase 3: TRIUMPH Program

Trial Status: Recruiting Clinical Trials Identifier: NCT06797869 Trial Name: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Diabetes Type: Type 2 diabetes Trial Sponsor: Novo Nordisk A/S Why is this study important

Since NAD is such an influential and prolific molecule in the body, high-dose IV therapy can be helpful for many different conditions, including: What to expect: Your treatment plan will consist of NAD+ infusions

PubMed, Awuchi, Chinaza Godseill, et al

This process markedly reduces urinary carnitine loss and is essential for maintaining systemic free carnitine homeostasis and supporting fatty acid -oxidation in high-energy-demand tissues such as the heart and skeletal muscle [95]

Check out our white paper, Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy, on how an integrated pharmacy model improves adherence and reduces out-of-pocket costs for GLP1 drugs.